The gene JUND has been shown to modulate the development of drug resistance in a majority of patients on Bortezomib-based anti-myeloma therapy [42]; three of the miRNAs identified in the original study as regulators of JUND were predicted using our MD model. This evidence concerns the gene JUND and plasma cell myeloma.